Page last updated: 2024-11-08

dimethylphenylpiperazinium iodide and Glucose Intolerance

dimethylphenylpiperazinium iodide has been researched along with Glucose Intolerance in 1 studies

Dimethylphenylpiperazinium Iodide: A selective nicotinic cholinergic agonist used as a research tool. DMPP activates nicotinic receptors in autonomic ganglia but has little effect at the neuromuscular junction.

Glucose Intolerance: A pathological state in which BLOOD GLUCOSE level is less than approximately 140 mg/100 ml of PLASMA at fasting, and above approximately 200 mg/100 ml plasma at 30-, 60-, or 90-minute during a GLUCOSE TOLERANCE TEST. This condition is seen frequently in DIABETES MELLITUS, but also occurs with other diseases and MALNUTRITION.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Clemmensen, C1
Jall, S1
Kleinert, M1
Quarta, C1
Gruber, T1
Reber, J1
Sachs, S1
Fischer, K1
Feuchtinger, A1
Karlas, A1
Simonds, SE1
Grandl, G1
Loher, D1
Sanchez-Quant, E1
Keipert, S1
Jastroch, M1
Hofmann, SM1
Nascimento, EBM1
Schrauwen, P1
Ntziachristos, V1
Cowley, MA1
Finan, B1
Müller, TD1
Tschöp, MH1

Other Studies

1 other study available for dimethylphenylpiperazinium iodide and Glucose Intolerance

ArticleYear
Coordinated targeting of cold and nicotinic receptors synergistically improves obesity and type 2 diabetes.
    Nature communications, 2018, 10-23, Volume: 9, Issue:1

    Topics: Adipose Tissue, Brown; Animals; Body Weight; Cold Temperature; Diabetes Mellitus, Type 2; Diet; Dime

2018